Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 98   

Articles published

LGND 85.85 -1.00 (-1.15%)
price chart
Ligand Pharmaceuticals Inc Stock Downgraded (LGND)
LIGAND PHARMACEUTICAL INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
Related articles »  
Apple Inc. (AAPL), Google Inc (GOOG), Ligand Pharmaceuticals Inc. (LGND ...
Adam Wright and Gary Kohler's Blue Clay Capital performed much better than Index Funds in the first quarter, as its 27 long positions in stocks with a market cap above $1.0 billion as reported in its latest 13F filinghad weighted average returns of 15.4%.
Ligand Pharmaceuticals Inc. (LGND) Largest Owner Sells Shares
Raising prospects for a continued deterioration in the stock price of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), the largest shareholder in the company has moved to unload shares of the troubled company in a private transactions.
Related articles »  
Why Lemelson Capital Is Short On Ligand Pharmaceuticals
Rev. Emmanuel Lemelson is the chief investment officer of Lemelson Capital Management, an investment firm that is short in Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Lemelson recently joined Benzinga's #PreMarket Prep to talk about why he thinks ...
Related articles »  
Lemeson Ups Ligand Pharmaceuticals Inc. (LGND) Short
Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and appended with additional concerns its initial June 16, 2014 research ...
Ligand Pharmaceuticals: Appendix  Seeking Alpha
Related articles »  
Ligand Pharmaceuticals (LGND) Shares March Higher, Can It Continue?
Investors certainly have to be happy with Ligand Pharmaceuticals Inc. (LGND - Snapshot Report) and its short term performance.
Ligand Pharmaceuticals Inc. (LGND), Inovio Pharmaceuticals Inc (INO), & Tejon ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Inovio Pharmaceuticals Inc (NASDAQ:INO) are two stocks from the pharma space that have recently seen insiders buying shares in large quantities.
Related articles »  
Ligand Licenses Captisol-enabled´┐Ż Lamotrigine to CURx Pharmaceuticals, Inc.
SAN DIEGO, Sep 09, 2014 (BUSINESS WIRE) -- Ligand Pharmaceuticals Incorporated LGND, +0.15% announced it has expanded its global license agreement with CURx Pharmaceuticals, Inc. to also include the development and commercialization of ...
Related articles »  
Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4?
The company said on its third-quarter 2014 call that demand for Captisol increased from new customers as well as several supply contracts supporting large late-stage studies.
Deutsche Bank Raises Ligand Pharmaceuticals Price Target to $94.00 (LGND)
Ligand Pharmaceuticals Inc. logo Ligand Pharmaceuticals (NASDAQ:LGND) had its price target increased by Deutsche Bank from $74.00 to $94.00 in a research report sent to investors on Wednesday morning.